Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma

World Journal of Urology

Volumn 31, Issue 4, 2013, Pages 841-846

  Gilles, Rozemarie ^a   de Geus Oei, Lioe Fee ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FDG; Immunotherapy; PET; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; INTERLEUKIN 2; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84881084626     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0723-y     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917. doi: 10. 1002/ijc. 25516.
2. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12(1): 206-212.
3. Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2006) Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int 97(5): 916-922. doi: 10. 111/j. 1464-410x. 2006. 06125. x.
4. Vugrin D (1987) Systemic therapy of metastatic renal cell carcinoma. Semin Nephrol 7(2): 152-162.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3): 205-221.
6. Delbeke D (1999) Oncological applications of FDG PET imaging: brain tumours, colorectal cancer, lymphoma and melanoma. J Nucl Med 40(4): 591-603.
7. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23(12): 1641-1674.
8. 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44(8): 1223-1225.
9. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124(2): 608-613.
10. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ (2008) Chemotherapy response evaluation with FDG PET in patients with colorectal cancer. Ann Oncol 19(2): 348-352. doi: 10. 1093/annonc/mdm470.
11. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG (2007) Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 9(5): 308-317. doi: 10. 1007/s11307-607-0103-6.
12. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumours. J Nucl Med 45(1): 17-21.
13. Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet JP, fau-Larue MH, Meignan M, Talbot JN, Molinier-Frenkel V (2007) [F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunol Immunother 56(8): 1163-1171. doi: 10. 1007/s00262-006-0265-0.
14. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL (2000) Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 41(6): 999-1005.
15. 18F-FDG PET studies. J Nucl Med 47(6): 945-949.
16. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3(1): 1-7.
17. van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH (2000) Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch immunotherapy working party. Br J Cancer 82(4): 772-776. doi: 10. 1054/bjoc. 1999. 0997.
18. Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, Leader M (1993) c-myc expression in renal carcinoma: correlation with clinical parameters. Br J Urol 72(2): 143-147.
19. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275(29): 21797-21800. doi: 10. 1074/bjc. c000023200.
20. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G (1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179(2): 157-161. doi: 10. 1002/(SICI)1096-9896(199606)179: 2<157: AID-PATH557>3. 0. CO;2-S.
21. Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B (2008) Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int 101(4): 480-484. doi: 10. 1111/j. 1464-410X. 2007. 07238. x.
22. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171(5): 1806-1809. doi: 10. 1097/01. ju. 0000120241. 50061. e4.
23. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T (2006) Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33(6): 683-691. doi: 10. 1007/s00259-005-0044-8.
24. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC (2004) Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25(1): 11-17. doi: 00006231-200401000-00003.
25. Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9(1): 15-18.
26. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, Bolton DM, Scott AM (2005) Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96(4): 540-546. doi: 10. 1111/j. 1464-410X. 2005. 05681. x.
27. Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD (1995) Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36(9): 1595-1601.
28. Brouwers A, Verel I, van Eerd EJ, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, van Wylen DG, Boerman O (2004) PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 19(2): 155-163. doi: 10. 1089/108497804323071922.